Literature DB >> 22001913

Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder.

Weerasak Chonchaiya1, Jacky Au, Andrea Schneider, David Hessl, Susan W Harris, Meredith Laird, Yi Mu, Flora Tassone, Danh V Nguyen, Randi J Hagerman.   

Abstract

Seizures are a common co-occurring condition in those with fragile X syndrome (FXS), and in those with idiopathic autism spectrum disorder (ASD). Seizures are also associated with ASD in those with FXS. However, little is known about the rate of seizures and how commonly these problems co-occur with ASD in boys with the FMR1 premutation. We, therefore, determined the prevalence of seizures and ASD in boys with the FMR1 premutation compared with their sibling counterparts and population prevalence estimates. Fifty premutation boys who presented as clinical probands (N = 25), or non-probands (identified by cascade testing after the proband was found) (N = 25), and 32 non-carrier controls were enrolled. History of seizures was documented and ASD was diagnosed by standardized measures followed by a team consensus of ASD diagnosis. Seizures (28%) and ASD (68%) were more prevalent in probands compared with non-probands (0 and 28%), controls (0 and 0%), and population estimates (1 and 1.7%). Seizures occurred more frequently in those with the premutation and co-morbid ASD particularly in probands compared with those with the premutation alone (25 vs. 3.85%, p = 0.045). Although cognitive and adaptive functioning in non-probands were similar to controls, non-probands were more likely to meet the diagnosis of ASD than controls (28 vs. 0%, p < 0.0001). In conclusion, seizures were relatively more common in premutation carriers who presented clinically as probands of the family and seizures were commonly associated with ASD in these boys. Therefore, boys with the premutation, particularly if they are probands should be assessed carefully for both ASD and seizures.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001913      PMCID: PMC4105134          DOI: 10.1007/s00439-011-1106-6

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  46 in total

1.  Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.

Authors:  Faraz Farzin; Hazel Perry; David Hessl; Danuta Loesch; Jonathan Cohen; Susan Bacalman; Louise Gane; Flora Tassone; Paul Hagerman; Randi Hagerman
Journal:  J Dev Behav Pediatr       Date:  2006-04       Impact factor: 2.225

2.  The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism.

Authors:  C Lord; S Risi; L Lambrecht; E H Cook; B L Leventhal; P C DiLavore; A Pickles; M Rutter
Journal:  J Autism Dev Disord       Date:  2000-06

3.  Epilepsy and EEG findings in males with fragile X syndrome.

Authors:  S A Musumeci; R J Hagerman; R Ferri; P Bosco; B Dalla Bernardina; C A Tassinari; G B De Sarro; M Elia
Journal:  Epilepsia       Date:  1999-08       Impact factor: 5.864

4.  An open trial of divalproex sodium in autism spectrum disorders.

Authors:  E Hollander; R Dolgoff-Kaspar; C Cartwright; R Rawitt; S Novotny
Journal:  J Clin Psychiatry       Date:  2001-07       Impact factor: 4.384

Review 5.  Autism spectrum disorders and epilepsy: moving towards a comprehensive approach to treatment.

Authors:  Roberto Tuchman; Michael Alessandri; Michael Cuccaro
Journal:  Brain Dev       Date:  2010-06-16       Impact factor: 1.961

Review 6.  Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X.

Authors:  Danuta Z Loesch; Quang M Bui; Cheryl Dissanayake; Sally Clifford; Emma Gould; Danuta Bulhak-Paterson; Flora Tassone; Annette K Taylor; David Hessl; Randi Hagerman; Richard M Huggins
Journal:  Neurosci Biobehav Rev       Date:  2006-11-09       Impact factor: 8.989

7.  Prevalence of epilepsy and epileptic seizures in 10-year-old children: results from the Metropolitan Atlanta Developmental Disabilities Study.

Authors:  C C Murphy; E Trevathan; M Yeargin-Allsopp
Journal:  Epilepsia       Date:  1995-09       Impact factor: 5.864

8.  Linking the FMR1 alleles with small CGG expansions with neurodevelopmental disorders: preliminary data suggest an involvement of epigenetic mechanisms.

Authors:  Danuta Z Loesch; David E Godler; Mahmoud Khaniani; Emma Gould; Freya Gehling; Cheryl Dissanayake; Trent Burgess; Flora Tassone; Richard Huggins; Howard Slater; K H Andy Choo
Journal:  Am J Med Genet A       Date:  2009-10       Impact factor: 2.802

9.  Prevalence of epilepsy in Rochester, Minnesota: 1940-1980.

Authors:  W A Hauser; J F Annegers; L T Kurland
Journal:  Epilepsia       Date:  1991 Jul-Aug       Impact factor: 5.864

10.  Seizure visits in US emergency departments: epidemiology and potential disparities in care.

Authors:  Daniel J Pallin; Joshua N Goldstein; Jon S Moussally; Andrea J Pelletier; Alexander R Green; Carlos A Camargo
Journal:  Int J Emerg Med       Date:  2008-06-05
View more
  69 in total

Review 1.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 2.  Advanced technologies for the molecular diagnosis of fragile X syndrome.

Authors:  Flora Tassone
Journal:  Expert Rev Mol Diagn       Date:  2015-10-21       Impact factor: 5.225

3.  Abnormal dendrite and spine morphology in primary visual cortex in the CGG knock-in mouse model of the fragile X premutation.

Authors:  Robert F Berman; Karl D Murray; Gloria Arque; Michael R Hunsaker; H Jürgen Wenzel
Journal:  Epilepsia       Date:  2012-06       Impact factor: 5.864

Review 4.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

5.  Broad autism spectrum and obsessive-compulsive symptoms in adults with the fragile X premutation.

Authors:  A Schneider; C Johnston; F Tassone; S Sansone; R J Hagerman; E Ferrer; S M Rivera; D Hessl
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

6.  Microglial cell activation and senescence are characteristic of the pathology FXTAS.

Authors:  Verónica Martínez Cerdeño; Tiffany Hong; Sarwat Amina; Mirna Lechpammer; Jeanelle Ariza; Flora Tassone; Stephen C Noctor; Paul Hagerman; Randi Hagerman
Journal:  Mov Disord       Date:  2018-12-10       Impact factor: 10.338

Review 7.  [Fragile X associated tremor/ataxia syndrome: its clinical presentation, pathology, and treatment].

Authors:  M J Salcedo-Arellano; R J Hagerman; V Martinez-Cerdeno
Journal:  Rev Neurol       Date:  2019-03-01       Impact factor: 0.870

8.  Epilepsy drives autism in neurodevelopmental disorders.

Authors:  Randi J Hagerman
Journal:  Dev Med Child Neurol       Date:  2013-02       Impact factor: 5.449

9.  Dysregulated iron metabolism in the choroid plexus in fragile X-associated tremor/ataxia syndrome.

Authors:  Jeanelle Ariza; Craig Steward; Flora Rueckert; Matt Widdison; Robert Coffman; Atiyeh Afjei; Stephen C Noctor; Randi Hagerman; Paul Hagerman; Verónica Martínez-Cerdeño
Journal:  Brain Res       Date:  2014-12-09       Impact factor: 3.252

10.  Influence of the fragile X mental retardation (FMR1) gene on the brain and working memory in men with normal FMR1 alleles.

Authors:  Jun Yi Wang; David Hessl; Christine Iwahashi; Katherine Cheung; Andrea Schneider; Randi J Hagerman; Paul J Hagerman; Susan M Rivera
Journal:  Neuroimage       Date:  2012-10-12       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.